Pelacarsen’s 2025 Failure: What’s Next for Lp(a)?

Dr. Anya Sharma, a cardiologist at Piedmont Atlanta Hospital, stared at Mrs. Eleanor Vance’s latest lab results. Eleanor, a lively 68-year-old, had diligently managed her cholesterol for decades, but her lipoprotein(a), or Lp(a), remained stubbornly high. The news that Pelacarsen, a promising antisense oligonucleotide developed by Amgen and Novartis, had failed its primary endpoint in the OCEAN(a)-Outcomes study in late 2025 hit the medical community hard, leaving many, including Dr. Sharma, questioning the viability of Lp(a) targets in drug research for heart disease. Does this setback mean the end for a promising avenue in pharma innovation?

For years, Eleanor had been an ideal patient. Her LDL cholesterol was well-controlled with a high-intensity statin, her blood pressure was optimal, and she walked five miles daily. Yet, her Lp(a) level consistently hovered above 150 nmol/L, a threshold widely recognized as high risk. “It’s a genetic lottery I didn’t win,” Eleanor often joked, though the underlying concern was always present. Dr. Sharma understood this worry. Elevated Lp(a) is an independent, genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis, a fact supported by extensive research over the past two decades. According to a consensus statement from the European Atherosclerosis Society, Lp(a) levels above 50 mg/dL (approximately 125 nmol/L) are associated with a significantly increased risk of heart attack and stroke, even in individuals with otherwise healthy lipid profiles.

The anticipation surrounding Pelacarsen had been immense. It was designed to specifically reduce Lp(a) production in the liver, and early phase trials showed impressive reductions, sometimes by as much as 80%. When the OCEAN(a)-Outcomes trial results were announced, revealing that Pelacarsen did not meet its primary endpoint of reducing major adverse cardiovascular events (MACE) compared to placebo, the collective sigh of disappointment from cardiologists and patients alike was almost palpable. “We thought we had a direct hit,” Dr. Sharma recounted, leaning back in her office chair, the glow of her monitor reflecting in her glasses. “The mechanism was sound, the Lp(a) reduction was clear. But it didn’t translate.”

This outcome forced a critical re-evaluation within the pharmaceutical industry and the medical community. Was the target itself flawed, or was it the approach? Dr. Sharma believes the latter. “The issue wasn’t Lp(a) itself,” she insists, “but perhaps our understanding of how to intervene effectively in such a complex disease process.” She points to the fact that cardiovascular disease is multifactorial. Simply lowering one risk marker, even a potent one like Lp(a), might not be enough if other pathways of atherosclerosis are not simultaneously addressed, or if the intervention comes too late in the disease progression for some patients.

The narrative of drug development is rarely a straight line. Failures, while disheartening, often provide important insights that guide subsequent research. After Pelacarsen, several other companies continued their pursuit of Lp(a)-lowering therapies. One prominent example is the development of small interfering RNA (siRNA) treatments. These drugs work by silencing the gene responsible for Lp(a) production. Olpasiran, developed by Amgen, and Zilebesiran, from Alnylam Pharmaceuticals, are two such candidates. These siRNA therapies have shown even more deep and sustained reductions in Lp(a) levels in early-stage trials than Pelacarsen. A study published in The New England Journal of Medicine in 2023 demonstrated that a single dose of olpasiran could reduce Lp(a) by up to 90% for months. This level of reduction is unprecedented and reignited hope.

Eleanor, always keen to stay informed about her condition, often asked Dr. Sharma about these new developments. “So, another shot at it, doctor?” she’d ask during her appointments. Dr. Sharma would nod cautiously. “These are different mechanisms, Eleanor. The siRNA drugs are designed for a more potent and longer-lasting effect. We’re also learning more about patient selection.” This nuanced approach is critical. Researchers are now exploring whether patients with extremely high Lp(a) levels, or those with a history of early-onset cardiovascular disease despite optimal traditional risk factors, might benefit most from these targeted therapies. It’s about finding the right patient for the right treatment, not a one-size-fits-all solution.

The pharmaceutical industry’s investment in Lp(a) remains substantial. While Pelacarsen’s trial outcome was a blow, it hasn’t deterred the overall commitment. Companies recognize the large unmet medical need. Millions globally have elevated Lp(a), and for many, current therapies do not adequately mitigate their risk. The global market for cardiovascular drugs is projected to reach over $150 billion by 2028, according to market analysis reports, and Lp(a) inhibitors are expected to capture a significant share if successful. This financial incentive, coupled with the clear scientific rationale, fuels continued innovation.

Beyond siRNA, other novel approaches are being investigated. These include gene-editing technologies, though these are much further down the pipeline. The goal across all these efforts is not just to lower Lp(a) but to prove that this reduction unequivocally leads to fewer heart attacks, strokes, and cardiovascular deaths. That is the ultimate benchmark for any new cardiovascular drug. The Pelacarsen trial, while disappointing in its primary outcome, did provide valuable data on safety and tolerability, which informs future trial designs.

Dr. Sharma firmly believes that Lp(a) targets are still viable, perhaps even more so now that the initial hurdle has provided a clearer path forward. “We learned what didn’t work, or at least, what didn’t work in that specific context,” she states. “That knowledge is invaluable. It forces us to refine our hypotheses, to design better trials, and to consider combination therapies.” She anticipates a future where Lp(a)-lowering drugs might be used in conjunction with statins or other lipid-lowering agents, or prescribed to patients at specific stages of their disease progression.

Eleanor Vance, for her part, continues her proactive management. She follows Dr. Sharma’s advice, maintains her healthy lifestyle, and takes her prescribed medications. The hope for a specific Lp(a)-lowering drug remains, but it’s tempered with realism. She understands that medical progress is incremental, built upon both successes and setbacks. The conversation around Lp(a) has shifted from a simple “will it work?” to a more complex “how will it work best, and for whom?” This evolution in understanding represents progress in itself, pushing the boundaries of drug research and heart disease treatment.

The future of Lp(a) targets in drug research is not about abandoning the goal, but about learning from initial attempts and adapting. The scientific community, bolstered by ongoing trials of next-generation therapies, is poised to deliver effective solutions for patients like Eleanor Vance. The journey is far from over, and the insights gained from past efforts are critical for working through the path ahead in pharma innovation.

The setback with Pelacarsen offers an important lesson: complex diseases require sophisticated solutions, often involving a deeper understanding of patient heterogeneity and combination therapies, not just single-target interventions. The pursuit of effective Lp(a) reduction remains a priority, driven by compelling evidence of its role in cardiovascular risk. For more on the pharmaceutical field and potential setbacks, see our article on what’s next for heart drugs in 2027.